Skip to main content

Advertisement

SpringerLink
Log in

Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future Prospects

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Hepatocellular carcinoma is the fourth leading cause of cancer-related deaths worldwide and its associated mortality rate is expected to rise within the next decade. The incidence rate of hepatocellular carcinoma varies significantly across countries and the latter can be attributed to the differences in risk factors that are prevalent across different countries. Some of the risk factors associated with hepatocellular carcinoma include hepatitis B and C infections, non-alcoholic fatty liver disease, and alcoholic liver disease. Regardless of the underlying aetiology, the end result is liver fibrosis and cirrhosis that ultimately progress into carcinoma. The treatment and management of hepatocellular carcinoma is complicated by treatment resistance and high tumor recurrence rates. Early stages of hepatocellular carcinoma are treated with liver resection and other forms of surgical therapy. Advanced stages of hepatocellular carcinoma can be treated with chemotherapy, immunotherapy, and the use of oncolytic viruses and these treatment options can be combined with nanotechnology to improve efficacy and reduce side effects. Moreover, chemotherapy and immunotherapy can be combined to further improve treatment efficacy and overcome resistance. Despite the treatment options available, the high mortality rates provide evidence that current treatment options for advanced-stage hepatocellular carcinoma are not achieving the desired therapeutic goals. Various clinical trials are ongoing to improve treatment efficacy, reduce recurrence rates, and ultimately prolong survival. This narrative review aims to provide an update on our current knowledge and future direction of research on hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular carcinoma in 2021: an exhaustive update, Cureus. 2021. https://doi.org/10.7759/cureus.19274

  2. Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clin Med. 2018;18(3):245–50. https://doi.org/10.7861/clinmedicine.18-3-245.

    Article  Google Scholar 

  3. Lotfollahzadeh S, Recio-Boiles A, Babiker H. Liver cancer, StatPearls Publishing, 2022. Available at: https://www.ncbi.nlm.nih.gov/books/NBK4. Accessed 20 Dec 2022

  4. Nancy F. Primary liver cancer: surveillance, diagnosis, and treatment. 1st ed. Connecticut: Humana Press; 2012.

    Google Scholar 

  5. Kim E, Viatour P. Hepatocellular carcinoma: old friends and new tricks. Exp Mol Med. 2020;52(12):1898–907. https://doi.org/10.1038/s12276-020-00527-1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Chidambaranathan-Reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification, Adv Cancer Res. 2021;1–61. doi: https://doi.org/10.1016/bs.acr.2020.10.001

  7. Lurje I, Czigany Z, Bednarsch J, Roderburg C, Isfort P, Neumann UP, et al. Treatment strategies for hepatocellular carcinoma – a multidisciplinary approach. Int J Mol Sci. 2019;20(6):1465. https://doi.org/10.3390/ijms20061465.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Samant H, Amiri H, Zibari G. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol. 2021;12(S2):S361–73. https://doi.org/10.21037/jgo.2020.02.08.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Dasgupta P, Henshaw C, Youlden DR, Clark PJ, Aitken JF, and Baade PD. Global trends in incidence rates of primary adult liver cancers: a systematic review and meta-analysis. Front Oncol. 2020;10. https://doi.org/10.3389/fonc.2020.00171

  10. • McGlynn K, Petrick J, El‐Serag H. Epidemiology of hepatocellular carcinoma. Hepatology. 2020;73(S1):4–13. https://doi.org/10.1002/hep.31288. This review demonstrated the impact of population’s demographic characteristics on the risk factors and incidence of HCC. In addition, it provided an overview on the epidemiology of HCC.

  11. Jiang H, Chen J, Xia C, Cao L, Duan T, Song B. Non-invasive imaging of hepatocellular carcinoma: from diagnosis to prognosis. World J Gastroenterol. 2018;24(22):2348–62. https://doi.org/10.3748/wjg.v24.i22.2348.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238–55. https://doi.org/10.1093/annonc/mdy308.

    Article  CAS  PubMed  Google Scholar 

  13. Fenton S, Burns M, Kalyan A. Epidemiology, mutational landscape and staging of hepatocellular carcinoma. Chin Clin Oncol. 2021;10(1):2–2. https://doi.org/10.21037/cco-20-162.

    Article  PubMed  Google Scholar 

  14. Bednarsch J, Czigany Z, Heise D, Joechle K, Luedde T, Heij L, et al. Prognostic evaluation of HCC patients undergoing surgical resection: an analysis of 8 different staging systems. Langenbeck’s Arch Surg. 2020;406(1):75–86. https://doi.org/10.1007/s00423-020-02052-1.

    Article  Google Scholar 

  15. Pinter M, Trauner M, Peck-Radosavlijec M, Seighart W. Cancer and liver cirrhosis: implications on prognosis and management. ESMO Open. 2016;1(2):e000042. https://doi.org/10.1136/esmoopen-2016-000042.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Khemlina G, Ikeda S, Kurzrock R. The biology of hepatocellular carcinoma: implications for genomic and immune therapies. Mol Cancer. 2017;16(1). https://doi.org/10.1186/s12943-017-0712-x.

  17. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. Clin Mol Hepatol. 2015;21(2):105. https://doi.org/10.3350/cmh.2015.21.2.105.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Nguyen MH, Wong G, Gane E, Kao J, Dushkeiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev. 2020;33(2). https://doi.org/10.1128/cmr.00046-19

  19. D’souza S, Lau KC, Coffin CS, Patel TR. Molecular mechanisms of viral hepatitis induced hepatocellular carcinoma. World J Gastroenterol. 2020;26(38):5759–83. https://doi.org/10.3748/wjg.v26.i38.5759.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Rocco A, Compare D, Angrisani D, SanduzziZamparelli M, Nardone G. Alcoholic disease: liver and beyond. World J Gastroenterol. 2014;20(40):14652. https://doi.org/10.3748/wjg.v20.i40.14652.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Neuschwander-Tetri B. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1). https://doi.org/10.1186/s12916-017-0806-8.

  22. Affo S, Yu L, Schwabe R. The role of cancer-associated fibroblasts and fibrosis in liver cancer. Annu Rev Pathol. 2017;12(1):153–86. https://doi.org/10.1146/annurev-pathol-052016-100322.

    Article  CAS  PubMed  Google Scholar 

  23. Dhar D, Baglieri J, Kisseleva T, Brenner DA. Mechanisms of liver fibrosis and its role in liver cancer. Exp Biol Med. 2020;245(2):96–108. https://doi.org/10.1177/1535370219898141.

    Article  CAS  Google Scholar 

  24. Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochimica et Biophysica Acta (BBA) - Rev Cancer. 2020;1873(1),188314. https://doi.org/10.1016/j.bbcan.2019.188314.

  25. Chen Z, Xie H, Hu M, Huang T, Hu Y, Sang N, and Zhao Y. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7539784/ (Accessed: 31 October 2022).

  26. Petruzzi P, Crocetti L, Lencioni R. Chemoembolization of hepatocellular carcinoma. Semin Interv Radiol. 2013;30(01):003–11. https://doi.org/10.1055/s-0033-1333648.

    Article  Google Scholar 

  27. Qiu Z, Li H, Zhang Z, Zhu Z, He S, Wang X, et al. A Pharmacogenomic landscape in human liver cancers. Cancer Cell. 2019;36(2):179-193.e11. https://doi.org/10.1016/j.ccell.2019.07.001.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. •• Kong FH, Ye QF, Miao XY, Liu X, Haung SQ, Xiong L, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma. Theranostics. 2021;11(11):5464–90. https://doi.org/10.7150/thno.54822. This review illustrates the constituents of nanoparticles and how they influence drug delivery. In addition, this paper provided insight into the different drug delivery systems with regard to sorafenib in the treatment of HCC.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. • Huang A, Yang XR, Chung WY, Dennison AR, and Zhou J. Targeted therapy for hepatocellular carcinoma. Sig Transduct Target Ther. 2020;5(1). https://doi.org/10.1038/s41392-020-00264-x. This paper provides an overview on different chemotherapy and immunotherapy agents available for the treatment of HCC and provides examples of chemotherapy agents used as sequential treatment to sorafenib

  30. •• Zhao Y, Zhang YN, Wang KT, and Chen L. Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy, Biochimica et Biophysica Acta (BBA) Rev Cancer. 2020;1874(1):188391. https://doi.org/10.1016/j.bbcan.2020.188391. This paper provides a summary of the mechanism of action of lenvatinib and describes clinical trials comparing lenvatinib with standard chemotherapy treatment. Additionally, this paper describes the results of clinical trials in which different combination therapy regimens are compared.

  31. Sangro B, Sarobe P, Herves-Stubbs, and Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8), 525-543. https://doi.org/10.1038/s41575-021-00438-0.

  32. •• Luo, X., Wu, K. and He, X. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets, J Exp Clin Cancer Res. 2021;40(1). https://doi.org/10.1186/s13046-021-01968-w. This review demonstrates the different therapy options available for HCC in terms of first-line and second-line treatments that are currently in use as well as therapy options that are at clinical trial stage.

  33. Xu F, Jin T, Zhu Y, and Dai C. Immune checkpoint therapy in liver cancer. J Exp Clin Cancer Res. 2018;37(1). https://doi.org/10.1186/s13046-018-0777-4.

  34. Sun JH, Luo Q, Liu LL. and Song GB Liver cancer stem cell markers: progression and therapeutic implications. World J Gastroenterol. 2016;22(13):3547. https://doi.org/10.3748/wjg.v22.i13.3547.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cao L, Zhu YQ, Wu ZX, Wang GX, Cheng HW. Engineering nanotheranostic strategies for liver cancer. World J Gastrointest Oncol. 2021;13(10):1213–28. https://doi.org/10.4251/wjgo.v13.i10.1213.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kaufman H, Kohlhapp F, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discovery. 2015;4(9):642–62. https://doi.org/10.1038/nrd4663.

    Article  CAS  Google Scholar 

  37. Li Y, Shen Y, Zhao R, Samudio I, Jia W, Bai X, et al. Oncolytic virotherapy in hepato-bilio-pancreatic cancer: the key to breaking the log jam? Cancer Med. 2020;9(9):2943–59. https://doi.org/10.1002/cam4.2949.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Li X, Sun X, Wang B, Li Y, Tong J. Oncolytic virus-based hepatocellular carcinoma treatment: current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J Pharm Sci. 2023;18(1):100771. https://doi.org/10.1016/j.ajps.2022.100771.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Nicosia Medical School, Nicosia, Cyprus

    Basil Alawyia MD

  2. Department of Basic and Clinical Sciences, University of Nicosia Medical School, P.O. Box 24005, 21 Ilia Papakyriakou, 2414 Engomi, CY-1700, Nicosia, Cyprus

    Constantina Constantinou PhD, MSc, BA

Authors
  1. Basil Alawyia MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Constantina Constantinou PhD, MSc, BA
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Constantina Constantinou PhD, MSc, BA.

Ethics declarations

Conflict of Interest

None of the authors has any potential conflicts of interest to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alawyia, B., Constantinou, C. Hepatocellular Carcinoma: a Narrative Review on Current Knowledge and Future Prospects. Curr. Treat. Options in Oncol. 24, 711–724 (2023). https://doi.org/10.1007/s11864-023-01098-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-023-01098-9

Keywords

Search

Navigation